Thursday, May 5, 2016

TearLab prices $17.3-million registered public offering

TearLab prices $17.3-million registered public offering

May 4, 2016 by · Leave a Comment 

Tweet TearLab (NASDAQ:TEAR; TSX:TLB) has priced a public offering of common stock to raised gross proceeds of approximately $17.3-million to close on May 9. The offering was priced at 75 cents a share of common stock, or common stock equivalent, with each share of common stock coupled with a warrant to purchase one-half of one […]

Rodman starts Bio-Path at buy

Rodman starts Bio-Path at buy

April 19, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday. “In our view, Bio-Path’s unique liposomal delivery of antisense DNA has the potential to significantly improve treatment outcomes in elderly patients (≥60 years) with acute myeloid […]

Rodman assumes coverage of NephroGenex at neutral

Rodman assumes coverage of NephroGenex at neutral

April 15, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of NephroGenex (NASDAQ:NRX) with a “neutral” rating and without a price target. The stock was quoted at 40 cents Friday afternoon. The board of NephroGenex decided in late February 2016 to pause the oral Pyridorin pivotal program in diabetic nephropathy, to effect a restructuring of […]

Rodman assumes coverage of Semler Scientific at buy

Rodman assumes coverage of Semler Scientific at buy

April 15, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of Semler Scientific (NASDAQ:SMLR) with a “buy” rating and $8 price target. The stock was quoted at $2.05 Friday afternoon. Semler’s 2015 revenue of $7-million represented growth of 93% over the 2014 revenue of $3.6-million. “In our view, the solid revenue growth demonstrates the continual […]

Rodman starts BioSpecifics at buy

Rodman starts BioSpecifics at buy

March 8, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has started coverage of BioSpecifics Technologies (NASDAQ:BSTC) with a “buy” rating and 12-month price target of $60. The stock closed at $35.97 on Monday. The company’s sole product is the collagenase clostridium histolyticum (CCH) for injection, which is approved for the treatment of Dupuytren’s contracture and Peyronie’s disease both in the […]

Rodman starts Nanosphere at buy

Rodman starts Nanosphere at buy

March 8, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of Nanosphere (NASDAQ:NSPH) with a “buy” rating and price target of $2. The stock closed at 87 cents on Monday. “In our view, the company’s Verigene system and test panels are differentiated from competing systems in that it is based on the gold nanoparticle technology for direct detection […]

Shaunak Deepak joins H.C. Wainwright

Shaunak Deepak joins H.C. Wainwright

March 8, 2016 by · Leave a Comment 

Tweet Shaunak Deepak has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group. Mr. Deepak previously was a VP and biotech analyst with Jefferies since 2009. He also has been an associate in the life sciences equity research departments of Piper Jaffray, Rodman & Renshaw and Stifel, Nicolaus. […]

Rodman starts VolitionRx at buy

Rodman starts VolitionRx at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday. “In our view, the company’s blood-based NuQ screening test for colorectal cancer, based on its proprietary nucleosomics epigenetic biomarker platform, is differentiated from traditional detection methods and […]

Rodman starts EyeGate Pharma at buy

Rodman starts EyeGate Pharma at buy

February 1, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday. “In our view, the company’s EGP-437 combination product is differentiated from eye drops and intraocular injections in that it is non-invasive and solves patient non-compliance and […]

Rodman starts BioBlast Pharma at buy

Rodman starts BioBlast Pharma at buy

January 28, 2016 by · Leave a Comment 

Tweet Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday. BioBlast is focused on platform-based solutions, addressing rare diseases due to mitochondrial dysfunction and misfolding of critical function proteins. The firm’s lead candidate and sole clinical asset, […]

Next Page »

Email Newsletters with Constant Contact
Google+